Search results for " Ly"

showing 10 items of 2487 documents

Comparative Study of the Efficacy of Olmesartan/Amlodipine vs. Perindopril/Amlodipine in Peripheral and Central Blood Pressure Parameters After Misse…

2016

Background Central aortic blood pressure (CBP) and CBP-derived parameters are independent predictors of cardiovascular risk. Angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors plus calcium channel blockers are the recommended first-line treatments in hypertensive diabetic patients; however, the effect in reducing CBP when a dose is skipped has not been established yet. The aim was to determine whether the fixed-dose combination of olmesartan/amlodipine (OLM/AML) provides equal efficacy and safety as the perindopril/AML (PER/AML) combination in reducing CBP, augmentation index (AIx), and pulse wave velocity (PWV) when a drug dose is missed. Methods In this no…

Malemedicine.medical_specialtyMissed DoseFixed-dose combinationUrologyTetrazolesolmesartanPulse Wave Analysisamlodipine030204 cardiovascular system & hematologyNO03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal MedicinemedicinePerindoprilHumans030212 general & internal medicineAmlodipineamlodipine antihypertensive agents blood pressure diabetes mellitus olmesartan perindoprilPulse wave velocityAgedbusiness.industryImidazolesblood pressureMiddle Agedantihypertensive agentsBlood pressureDiabetes Mellitus Type 2Hypertensiondiabetes mellitusAortic pressureFemaleperindoprilOlmesartanbusinessmedicine.drugAmerican Journal of Hypertension
researchProduct

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

2009

Background Acquired somatic deletions and loss-of-function mutations in one or several codons of the TET2 ( Ten-Eleven Translocation-2 ) gene were recently identified in hematopoietic cells from patients with myeloid malignancies, including myeloproliferative disorders and myelodys-plastic syndromes. The present study was designed to determine the prevalence of TET2 gene alterations in chronic myelomonocytic leukemias. Design and Methods Blood and bone marrow cells were collected from 88 patients with chronic phase chronic myelomonocytic leukemia and from 14 with acute transformation of a previously identified disease. Polymerase chain reaction analysis and direct sequencing were used to se…

Malemedicine.medical_specialtyMyeloidDNA Mutational AnalysisChronic myelomonocytic leukemiaSingle-nucleotide polymorphismKaplan-Meier EstimateGene mutationBiologymedicine.disease_causeDioxygenasesGene FrequencyMonocytosisInternal medicinehemic and lymphatic diseasesProto-Oncogene ProteinsmedicineHumansGenetic Predisposition to DiseaseLetters to the EditorAgedProportional Hazards ModelsAged 80 and overComparative Genomic HybridizationMutationHematologyLeukemia Myelomonocytic ChronicHematologyMiddle Agedmedicine.diseaseMyelodysplastic-Myeloproliferative DiseasesDNA-Binding ProteinsLeukemiamedicine.anatomical_structureImmunologyMutationFemaleOriginal Article
researchProduct

Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study

2014

The outcome of high-risk (HR) Acute Lymphoblastic Leukemia (ALL) patients enrolled in AIEOP-BFM ALL 2000 study (NCT00613457) in Italy is described. Overall, 1999 Philadelphia negative ALL patients entered the study. HR criteria were: minimal residual disease (MRD) levels ≥10-3 at day 78 (HR-MRD), no complete remission (no-CR) at day 33, t(4;11) translocation, Prednisone Poor Response (PPR). Treatment (2 years) included protocol I, 3 polychemotherapy blocks, delayed intensification (protocol IIx2 or IIIx3), cranial radiotherapy, maintenance. 312 HR patients (15.6% of the total) had 5-year event-free survival (EFS) and overall survival (OS) of 58.9%(SE 2.8) and 68.9%(2.6). In hierarchical ord…

Malemedicine.medical_specialtyNeoplasm ResidualAdolescentmedicine.medical_treatmentImmunologyChromosomal translocationhigh riskacute lymphoblastic leukemiaHematopoietic stem cell transplantationBiochemistryGastroenterologyAdolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child Preschool; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Neoplasm Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy; Remission Induction; Treatment Outcome; Hematology; Biochemistry; Cell Biology; ImmunologyPrednisonehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy Protocolshigh risk; acute lymphoblastic leukemiaHumansMedicineNeoplasmPreschoolChildChemotherapyAntineoplastic Combined Chemotherapy ProtocolRadiotherapybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationInfantCell BiologyHematologyPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseCombined Modality TherapyMinimal residual diseaseSurgeryClinical trialRadiation therapyTreatment OutcomeN/ASettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAResidualChild PreschoolNeoplasmFemalebusinessHumanmedicine.drugBlood
researchProduct

Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from th…

2013

International audience; BACKGROUND: Lymphoma occurring in patients aged 90 or older is not uncommon, and its incidence is expected to increase over time. Management of these patients is difficult given their underlying fragility and the lack of information regarding this population. PATIENTS AND METHODS: We retrospectively analyzed 234 patients diagnosed with lymphoma at the age of 90 years or older (90+) between 1990 and 2012 to describe their characteristics, management, outcomes and prognostic factors. RESULTS: The median age was 92 years; 88% were B-cell lymphomas consisting mainly in diffuse large B-cell lymphoma. The median overall survival (OS) was 7.2 months (range, 0-92 months) for…

Malemedicine.medical_specialtyPalliative careSurvivalPopulation[SDV.CAN]Life Sciences [q-bio]/Cancerlymphoma[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicine[SDV.CAN] Life Sciences [q-bio]/Cancerimmune system diseasesInternal medicinehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansHypoalbuminemiaeducationSerum Albumin030304 developmental biologyCause of deathRetrospective StudiesAged 80 and over0303 health scienceseducation.field_of_studypalliative carebusiness.industryIncidence (epidemiology)IncidenceLymphoma Non-HodgkinHematologymedicine.diseasePrognosisComorbidity3. Good healthLymphomaSurgeryaged 80 and overcomorbidityOncology030220 oncology & carcinogenesisFemaleLymphoma Large B-Cell DiffusebusinessDiffuse large B-cell lymphoma
researchProduct

Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms

2009

The evidence that leukocytes may contribute to the pathogenesis of thrombosis in Chronic Myeloproliferative Neoplasms is increasing but not definitive. To further enforces whether an increased leukocyte count is associated with thrombosis and whether this effect can be modulated by cytoreductive therapy, we analyzed the clinical course of 187 patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) followed at two Italian Institutions over a period of 7 years. The association was measured at diagnosis or before thrombotic events: a multivariable analysis was carried out using data at baseline and time-dependent covariates. We found that white blood cells (WBC) count above 9.5…

Malemedicine.medical_specialtyPathologyLeukocytosismyeloproliferative neoplasm thrombosis jak2GastroenterologyLeukemia Myeloid Chronic Atypical BCR-ABL NegativeSettore MED/15 - Malattie Del SangueLeukocyte CountPolycythemia verahemic and lymphatic diseasesInternal medicinemedicineHumansHydroxyureaLeukocytosisRisk factorProspective cohort studyPolycythemia VeraMyeloproliferative neoplasmAgedbusiness.industryEssential thrombocythemiaHazard ratioThrombosisHematologyGeneral MedicineJanus Kinase 2Middle Agedmedicine.diseaseThrombosisMultivariate AnalysisFemalemedicine.symptombusinessThrombocythemia Essential
researchProduct

Reversible posterior leukoencephalopathy syndrome in a patient with thrombotic thrombocytopenic purpura

2011

Thrombotic thrombocytopenic purpura (TTP) is an autoimmune disorder characterised by fever, microangiopathic haemolytic anaemia, renal insufficiency, and thrombocytopenia. Neurological involvement, a prominent component of TTP, is characterised by a variety of brain lesions which include reversible cerebral oedema or magnetic resonance imaging (MRI) features of reversible posterior leukoencephalopathy syndrome (RPLS). TTP is frequently associated with deficiency of the von Willebrand factor-cleaving protease, ADAMTS13.Here, we report a case of TTP with severe acute encephalopathy. Posterior leukoencephalopathy and brainstem oedema with triventricular hydrocephalus were observed on MRI. The …

Malemedicine.medical_specialtyPathologyNeurologyThrombotic thrombocytopenic purpuraAnti-Inflammatory AgentsDermatologyMethylprednisolonehemic and lymphatic diseasesmedicineHumansmedicine.diagnostic_testbusiness.industryMagnetic resonance imagingGeneral MedicinePlasmapheresisMiddle Agedmedicine.diseaseReversible posterior leukoencephalopathy Thrombotic thrombocytopenic purpura ADAMTS-13Plasma exchangeADAMTS13SchistocyteSurgeryHydrocephalusPsychiatry and Mental healthPurpuraTreatment OutcomeMethylprednisolonePurpura ThrombocytopenicSettore MED/26 - NeurologiaNeurology (clinical)Posterior Leukoencephalopathy Syndromemedicine.symptombusinessmedicine.drug
researchProduct

Factor V Leiden and prothrombin gene mutation in inflammatory bowel disease in a Mediterranean area.

2001

Abstract Background. Thromboembolism has been reported to be associated with inflammatory bowel disease. Aim. To evaluate the association of factor V Leiden and prothrombin gene mutation with inflammatory bowel disease in a population of patients with thromboembolic events and inflammatory bowel disease and in a control population of patients with inflammatory bowel disease without thromboembolic events. Patients and methods. A series of 18 patients with inflammatory bowel disease and a history of arterial or venous thrombosis and 45 patients with inflammatory bowel disease without thromboembolic events were evaluated for the presence of factor V Leiden and prothrombin gene mutation. Freque…

Malemedicine.medical_specialtyPathologyProthrombin gene mutationPopulationGene mutationGastroenterologyInflammatory bowel diseaseCrohn Diseasehemic and lymphatic diseasesInternal medicineThromboembolismFactor V LeidenmedicinePrevalenceHumansPoint Mutationeducationeducation.field_of_studyHepatologybusiness.industryMediterranean RegionGastroenterologyFactor VMiddle Agedmedicine.diseaseVenous thrombosisMediterranean areaColitis UlcerativeFemaleProthrombinFactor V Leiden mutationbusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Survival of Mycosis Fungoides in Patients in the Southeast of England

2004

<i>Background:</i> Mycosis fungoides (MF) is the most common skin lymphoma. The aetiology of MF remains unknown, and no therapy has to date significantly altered patient survival. <i>Objective:</i> The present study examines trends in survival of MF patients in a well-defined population-based disease group, namely patients registered over a 40-year period at the Thames Cancer Registry, Southeast England. <i>Methods:</i> The Thames Cancer Registry is a population-based registry, covering a population of approximately 14 million people. Data were taken from the Surveillance, Epidemiology and End Results cancer registry programme and the National Centre for …

Malemedicine.medical_specialtyPathologySkin NeoplasmsAntineoplastic Agents HormonalDermatologyCohort StudiesMycosis FungoidesSex FactorsResidence CharacteristicsEpidemiologymedicineHumansSezary SyndromeIn patientRegistriesSurvival rateAgedProportional Hazards ModelsMycosis fungoidesbusiness.industryProportional hazards modelAge FactorsMiddle AgedPrognosismedicine.diseaseDermatologyPeripheral T-cell lymphomaLymphomaSurvival RateEnglandPopulation SurveillanceEtiologyFemalebusinessFollow-Up StudiesSEER Program
researchProduct

Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy

2009

SUMMARY BACKGROUND: More and more people with severe hemophilia reach an old age thanks to an effective treatment. There is no information on the health status and quality of life of elderly people with hemophilia born at a time when replacement therapy was hardly available. METHODS: Italian patients with severe hemophilia, aged >or=65 years and hence born in 1942 or earlier, were compared with elderly men without bleeding disorders matched for age, sex, geography and social status. The following aspects were evaluated: concomitant illness, orthopedic status, physical functioning and cognitive status. Measurements of generic and disease-specific health-related quality of life were also obta…

Malemedicine.medical_specialtyPediatricshamophilia healt status agingActivities of daily livingHealth StatusPopulationActivities of Daily Living; Aged; Blood Coagulation Factors; Hemophilia A; Humans; Italy; Male; Health Status; Quality of LifeHemophilia ASettore MED/15 - Malattie Del SangueQuality of lifehemic and lymphatic diseasesArthropathyActivities of Daily LivingMedicineHumanseducationDepression (differential diagnoses)Agededucation.field_of_studybusiness.industryHematologymedicine.diseaseBlood Coagulation FactorsItalyConcomitantOrthopedic surgeryPhysical therapyQuality of LifebusinessSocial status
researchProduct

Hemorheological parameters in Monoclonal Gammopathy of Undetermined Significance (MGUS).

2018

There is scarcity of information about the hemorheological pattern in subjects with Monoclonal Gammopathy of Undetermined Significance (MGUS). This preliminary research is focused on the behaviour of whole-blood and plasma viscosity, haematocrit and erythrocyte deformability in the above clinical condition. We enrolled 21 MGUS subjects (10 women and 11 men; mean age 66.4 ± 11.6 years). In fasting venous blood we examined whole-blood and plasma viscosity at high and low shear rates, haematocrit, the ratios between whole-blood viscosity (at high and low shear rate) and haematocrit × 100, the ratio between plasma viscosity at low and high shear rate, and the erythrocyte deformability expressed…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaPhysiologyBlood viscosity030204 cardiovascular system & hematologyMonoclonal Gammopathy of Undetermined SignificanceSettore MED/15 - Malattie Del Sangue03 medical and health sciencesViscosity0302 clinical medicinehemic and lymphatic diseasesPhysiology (medical)Internal medicineErythrocyte DeformabilitymedicineErythrocyte deformabilityHumanscardiovascular diseasesPlasma viscosityParaproteinemia; blood viscosity; erythrocyte deformability; plasma viscosityAgedChemistryMean ageHematologyVenous bloodmedicine.diseaseBlood ViscosityShear rateParaproteinemiaEndocrinology030220 oncology & carcinogenesisplasma viscosityFemaleCardiology and Cardiovascular MedicineRheologyMonoclonal gammopathy of undetermined significanceClinical hemorheology and microcirculation
researchProduct